亚洲精品第五页中文字幕,7777久久亚洲中文字幕,亚洲一区无码中文字幕乱码

<ul id="so0mk"></ul>

BIOTECH FOR BETTER LIFE

By constructing a comprehensive value chain from R&D to manufacture of APIs and preparations, HVSEN Biotech is one of the TOP 10 animal health enterprises in China, and now has 4 factories, 2 R&D centers and 6 BUs. HVSEN is committed to supply safety and innovative products and solutions to domestic & aboard markets.

DEVELOPMENT HISTORY

1994---Brand Veterinary Medicine Retail Chain

2002---Establish Wuhan HVSEN Biotechnology Co., ltd

2007---Establish Wuhan Xinhuaxing Animal Health Chain Service Co., Ltd

2009---Acquisition of Spn Animal Pharmaceutical

2009---Establish Hubei HVSEN Biotechnology Co., ltd

2015---Comprehensive preparations and important production lines were put into operation

2017--- Hubei HVSEN Biotechnology Co., ltd. Expand Production

2018---Building Intelligent Plant

2020--- The 1000 tons of Tylosin tartrate project was put into operation

2020---Listed in the public company in Aug.2020

INNOVATION

HVSEN is focusing on the innovation of novel macrolides APIs and preparations, with 42 patents and 3 certificated novel APIs. It has been famous of tylvalosin raw material, various tylvalosin preparations, florfenicol preparations and other macrolides products in the market. Presently HVSEN has the capability of producing more than 50 veterinary drug products of raw materials & preparations, also some traditional Chinese medicines (TCMs) extractives.